Navigation Links
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Date:9/10/2007

dase human injection) if sensitization occurs. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection. Hyaluronidase should not be used to reduce the swelling of bites or stings. Hyaluronidase should not be applied directly to the cornea. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.

Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase. The most frequently reported adverse experiences have been local injection site reactions. Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug product. Allergic reactions (urticaria or angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely. When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidence of systemic reaction. Edema has been reported most frequently in association with hypodermoclysis.

The full prescribing information for HYLENEX should be consulted prior to prescription or administration. For full HYLENEX prescribing information, visit http://www.HYLENEX.com.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The comp
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Selexis ... for biologic drug discovery and mammalian cell line development, ... CHO-Mplus Libraries ™ will be presented at the 10th ... being held, September 8 – 10, 2014 at the ... , The following abstract will be presented during ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... Oct. 11 Generex Biotechnology Corporation (Nasdaq: GNBT ... initiate a rights offering of common stock and warrants to ... a reverse stock split at the reconvened special meeting of ... 2010.  The amount of the offering has not been determined, ...
... for Global Health (BVGH) announced today that G. Steven ... and James A. Geraghty, Senior Vice President, Genzyme Corporation, ... of these two new board members rounds out the ... in emerging markets and public-private partnerships. "Both ...
... PharmaTech (NYSE: WX ), a leading pharmaceutical, ... with operations in China and the United States, today ... Negishi, and Dr. Akira Suzuki on winning the 2010 ... the development of palladium-catalyzed cross coupling, which has vastly ...
Cached Biology Technology:Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 2Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 3Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 2Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 3WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry 2
(Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
(Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
(Date:7/30/2014)... has been awarded the Scientific Committee on Antarctic ... Research. , SCAR, an inter-disciplinary international science body, ... research in the Antarctic region, and on the ... system. The organisation also provides scientific advice about ... governing the region. , The medal is open ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2Decades-old amber collection offers new views of a lost world 2
... from farm fields often end up in aquatic ecosystems, resulting ... ,dead zones,. There are concerns that fertilizers used on lawns ... in the United States cover an area almost as large ... use a legitimate issue. In a study funded by ...
... Jude Children,s Research Hospital scientists has identified an unexpected ... of cells and, in the process, identified a potential ... a chemical known as an acetyl group. An estimated ... to the amino acid at one end of the ...
... Inserm has revealed how the measles virus leaves the body ... have identified a key receptor, located in the trachea, which ... one organism to another. The receptor, nectine-4, is also known ... appeared in a letter, dated 2 November 2011, published in ...
Cached Biology News:Nitrogen fertilizers' impact on lawn soils 2Molecule serves as a key in some protein interactions 2Molecule serves as a key in some protein interactions 3Why is the measles virus so contagious? 2
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: